EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Anna M Becker iD, Mélusine Humbert-Droz, Lorenz Mueller iD, Alen Jelušić, Avram Tolev, Isabelle Straumann, Isidora Avedisian, Livio Erne, Jan Thomann iD, Dino Luethi iD, Edna Grünblatt, Henriette Meyer Zu Schwabedissen iD und 1 weitere

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1784-1792

DOI: 10.1002/cpt.3618 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.02.2025. Verfasst von Anna M Becker und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology, Department of Biomedicine, Department of Clinical Research, University Hospital Basel and University of Basel, …. Hauptthemen laut MEDLINE: Paroxetine, Lysergic Acid Diethylamide, Selective Serotonin Reuptake Inhibitors, Hallucinogens. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants. Paroxetine did not alter pleasant subjective effects of LSD but significantly reduced “bad drug effect,” “anxiety,” and “nausea.” No differences in autonomic effects or QTc interval after LSD administration were found between both conditions. The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism. The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers. The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated. The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6. For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParoxetineLysergic Acid DiethylamideSelective Serotonin Reuptake InhibitorsHallucinogensCytochrome P-450 CYP2D6 InhibitorsHumansCross-Over StudiesDouble-Blind MethodMaleAdultFemaleYoung AdultCytochrome P-450 CYP2D6Drug InteractionsMiddle Aged

Substanzen

ParoxetineLysergic Acid DiethylamideCytochrome P-450 CYP2D6Selective Serotonin Reuptake InhibitorsHallucinogensCytochrome P-450 CYP2D6 Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology and Toxicology, Department of Biomedicine, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
  • Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
  • Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

ORCID-Profile: Anna M Becker, Lorenz Mueller, Jan Thomann, Dino Luethi, Henriette Meyer Zu Schwabedissen, Matthias E Liechti

Zitieren

APA

Becker, A. M., Humbert-Droz, M., Mueller, L., Jelušić, A., Tolev, A., Straumann, I., Avedisian, I., Erne, L., Thomann, J., Luethi, D., Grünblatt, E., Meyer Zu Schwabedissen, H., & Liechti, M. E. (2025). Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial. Clinical Pharmacology & Therapeutics, 117(6), 1784-1792. https://doi.org/10.1002/cpt.3618

Vancouver

Becker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, et al. Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial. Clinical Pharmacology & Therapeutics. 2025;117(6):1784-1792. doi:10.1002/cpt.3618

BibTeX
@article{Becker2025,
  author = {Becker, Anna M and Humbert-Droz, Mélusine and Mueller, Lorenz and Jelušić, Alen and Tolev, Avram and Straumann, Isabelle and Avedisian, Isidora and Erne, Livio and Thomann, Jan and Luethi, Dino and Grünblatt, Edna and Meyer Zu Schwabedissen, Henriette and Liechti, Matthias E},
  title = {Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1784--1792},
  doi = {10.1002/cpt.3618}
}
Kostenlos starten →